AstraZeneca Annual Report and Form 20-F Information 2011

Strategy and PerformanceOur performance in 2011 continuedPipelineMajor market approvals for Brilinta, Caprelsa, Axanum and Komboglyze TM ;Nexium and Faslodex 500mg approved in Japan; mixed results fordapagliflozin submission and disappointments on other pipeline products 2Deliver the businessGlobal revenue reduction of2% included 10% increase inEmerging Markets 4Product approvalsOne-two first major market approvals per year that support revenue target for 2014 of$3-5 3 billion from recent launches, pipeline and in-licensing2011: Brilinta approved in the US and Canada; Caprelsa (vandetanib) approvedin the US and positive CHMP opinion in the EU; Axanum approved in the EU,Komboglyze approved in the EU, Fluenz approved in the EU2010: Vimovo approved in the US and the EU; Brilique approved in the EU withComplete Response Letter received for Brilinta in the US; Kombiglyze XR approvedin the US; additional indications approved for Crestor in the US and the EU and forSeroquel XR in the EU2014 target reducedRegulatory submissionsMajor market submissions to support first approvals and line extensions for each newproduct, and continued marketing applications (first local authorisation and local lineextensions) in additional countries to drive growth2011: Nexium and Faslodex 500mg approved in Japan; dapagliflozin MAAvalidated by EMA; Complete Response Letter received from the FDA in the USrequesting additional clinical data2010: Dapagliflozin and vandetanib NDAs submitted in the US and the EU; Zinforo andAxanum MAAs submitted in the EUOn targetPhase III investment decisionsPhase III investment decisions that support value targets for new products 32011: Phase III trials started for NKTR-118 and initiation of Phase IIIprogramme for CAZ AVI2010: Phase III trials started for fostamatinib and TC-52142014 target reducedLicensing deals/acquisitions40% of our pipeline sourced from outside our laboratories2011:6 out of 9 Phase III/Registration projects (67%) sourced externally12 out of 24 Phase II projects (50%) sourced externally2010:6 out of 9 Phase III/Registration projects (67%) sourced externally11 out of 32 Phase II projects (34%) sourced externallyMet targetGrowth of key brandsDrive revenue growth of key brands thatretain exclusivity2011:Crestor +13%, Symbicort +11%,Seroquel XR +27%2010:Crestor +24%, Symbicort +20%,Seroquel XR +67%Met targetRevenue from new productlaunchesRevenue in 2014 in the range of$3-5 3 billion from recent launches,pipeline and in-licensing2011:$274mCombined revenue from Onglyza,Vimovo, Brilinta/Brilique, Caprelsaand Axanum2010: $74 millionCombined revenue from Onglyzaand Vimovo2014 target reducedEmerging Market sales25% of revenue in 2014 from EmergingMarkets business2011:17%17% of revenue fromEmerging Markets2010: 16% of revenue fromEmerging MarketsOn target2See Research and Development section from page 30 for more information.3Target revised to $2-4 billion in February 2012. See Medium-term planning assumptions section on page 22.4See Financial Review from page 82 and Therapy AreaReview from page 56 for more information.24 Strategy and Performance Our performance in 2011AstraZeneca Annual Report and Form 20-F Information 2011